Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2016-04

AUTHORS

Takamasa Ohki, Akihiro Isogawa, Nobuo Toda, Kazumi Tagawa

ABSTRACT

BACKGROUND: We previously reported that incretin-based drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogs, improved glycemic control and liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). However, the effect on alanine aminotransferase (ALT) normalization was still limited. AIMS: The aim of this study is to elucidate the effectiveness of sodium-glucose co-transporter 2 (SGLT-2) inhibitors as second-line treatments for NAFLD patients with T2DM who do not respond to incretin-based therapy. METHODS: We retrospectively enrolled 130 consecutive Japanese NAFLD patients with T2DM who were treated with GLP-1 analogs or DPP-4 inhibitors. Among them, 70 patients (53.8 %) had normal ALT levels. Of the remaining 60 patients (46.2 %) who did not have normal ALT levels, 24 (40.0 %) were enrolled in our study and were administered SGLT-2 inhibitors in addition to GLP-1 analogs or DPP-4 inhibitors. We compared changes in laboratory data including ALT levels and body weight at the end of the follow-up. RESULTS: Thirteen patients were administered a combination of SGLT-2 inhibitors with DPP-4 inhibitors, and the remaining 11 patients were administered a combination of SGLT-2 inhibitors with GLP-1 analogs. The median dosing period was 320 days. At the end of the follow-up, body weight (from 84.8 to 81.7 kg, p < 0.01) and glycosylated hemoglobin levels (from 8.4 to 7.6 %, p < 0.01) decreased significantly. Serum ALT levels also decreased significantly (from 62 to 38 IU/L, p < 0.01) with an improvement in the FIB-4 index (from 1.75 to 1.39, p = 0.04). Finally, 14 patients (58.3 %) achieved normalization of serum ALT levels. CONCLUSIONS: Administration of SGLT-2 inhibitors led to not only good glycemic control, but also to a reduction in body weight, normalization of ALT levels, and a reduction in the FIB-4 index even in patients who did not respond to incretin-based therapy. More... »

PAGES

313-319

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40261-016-0383-1

DOI

http://dx.doi.org/10.1007/s40261-016-0383-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1049428929

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26914659


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alanine Transaminase", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Diabetes Mellitus, Type 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipeptidyl-Peptidase IV Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucagon-Like Peptide 1", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Glucosides", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incretins", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Non-alcoholic Fatty Liver Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sodium-Glucose Transporter 2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Thiophenes", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Weight Loss", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Mitsui Memorial Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415980.1", 
          "name": [
            "Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, 101-8643, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ohki", 
        "givenName": "Takamasa", 
        "id": "sg:person.0735132461.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735132461.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsui Memorial Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415980.1", 
          "name": [
            "Department of Diabetes and Metabolism, Mitsui Memorial Hospital, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Isogawa", 
        "givenName": "Akihiro", 
        "id": "sg:person.0741074707.87", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741074707.87"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsui Memorial Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415980.1", 
          "name": [
            "Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, 101-8643, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toda", 
        "givenName": "Nobuo", 
        "id": "sg:person.01072014047.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072014047.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mitsui Memorial Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415980.1", 
          "name": [
            "Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, 101-8643, Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tagawa", 
        "givenName": "Kazumi", 
        "id": "sg:person.01141347054.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141347054.93"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.2337/diabetes.50.8.1844", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003096800"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1136/bmj.39335.541782.ad", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008007813"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0016-5085(98)70599-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012749798"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pharmthera.2013.04.003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016012961"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1464-5491.2009.02666.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022072850"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1210/jc.2004-1024", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022700049"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1542-3565(04)00440-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023338845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1542-3565(04)00440-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023338845"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jdiacomp.2012.11.005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025708927"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/jhep.2003.50193", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027809788"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0907929", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029275010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa060326", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029539751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.20251", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029810647"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.21178", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029848202"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.23276", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033130882"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejphar.2015.02.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034689807"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf03256922", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041484140", 
          "https://doi.org/10.1007/bf03256922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9343(03)00449-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041511618"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1100/2012/496453", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048327929"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2005.41583.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049736431", 
          "https://doi.org/10.1111/j.1572-0241.2005.41583.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1111/j.1572-0241.2003.07486.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049967292", 
          "https://doi.org/10.1111/j.1572-0241.2003.07486.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/hep.20466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051636461"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/11594330-000000000-00000", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069132279", 
          "https://doi.org/10.2165/11594330-000000000-00000"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5754/hge11263", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1073100437"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082321843", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-04", 
    "datePublishedReg": "2016-04-01", 
    "description": "BACKGROUND: We previously reported that incretin-based drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogs, improved glycemic control and liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). However, the effect on alanine aminotransferase (ALT) normalization was still limited.\nAIMS: The aim of this study is to elucidate the effectiveness of sodium-glucose co-transporter 2 (SGLT-2) inhibitors as second-line treatments for NAFLD patients with T2DM who do not respond to incretin-based therapy.\nMETHODS: We retrospectively enrolled 130 consecutive Japanese NAFLD patients with T2DM who were treated with GLP-1 analogs or DPP-4 inhibitors. Among them, 70 patients (53.8\u00a0%) had normal ALT levels. Of the remaining 60 patients (46.2\u00a0%) who did not have normal ALT levels, 24 (40.0\u00a0%) were enrolled in our study and were administered SGLT-2 inhibitors in addition to GLP-1 analogs or DPP-4 inhibitors. We compared changes in laboratory data including ALT levels and body weight at the end of the follow-up.\nRESULTS: Thirteen patients were administered a combination of SGLT-2 inhibitors with DPP-4 inhibitors, and the remaining 11 patients were administered a combination of SGLT-2 inhibitors with GLP-1 analogs. The median dosing period was 320\u00a0days. At the end of the follow-up, body weight (from 84.8 to 81.7\u00a0kg, p\u00a0<\u00a00.01) and glycosylated hemoglobin levels (from 8.4 to 7.6\u00a0%, p\u00a0<\u00a00.01) decreased significantly. Serum ALT levels also decreased significantly (from 62 to 38\u00a0IU/L, p\u00a0<\u00a00.01) with an improvement in the FIB-4 index (from 1.75 to 1.39, p\u00a0=\u00a00.04). Finally, 14 patients (58.3\u00a0%) achieved normalization of serum ALT levels.\nCONCLUSIONS: Administration of SGLT-2 inhibitors led to not only good glycemic control, but also to a reduction in body weight, normalization of ALT levels, and a reduction in the FIB-4 index even in patients who did not respond to incretin-based therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s40261-016-0383-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1100199", 
        "issn": [
          "1173-2563", 
          "1179-1918"
        ], 
        "name": "Clinical Drug Investigation", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors", 
    "pagination": "313-319", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "eb77f3ca414118c950dc9cabe52ba8dbbda22e7c63581dda65800f371e66f67d"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26914659"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "9504817"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40261-016-0383-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1049428929"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40261-016-0383-1", 
      "https://app.dimensions.ai/details/publication/pub.1049428929"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000524.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs40261-016-0383-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40261-016-0383-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40261-016-0383-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40261-016-0383-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40261-016-0383-1'


 

This table displays all metadata directly associated to this object as RDF triples.

230 TRIPLES      21 PREDICATES      69 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40261-016-0383-1 schema:about N0c7806a5a2c444c5b0868b808155d469
2 N169f5a2bf9544b3f881622a4e805cec9
3 N29df11f42e4147e38d7c6f35b862b2e7
4 N2df7bae69f5644338428fb078f46718d
5 N3ce57277b51d453f8dfdf154e250161e
6 N475a3997182b4b55b406e3736237bc79
7 N4d42e17b779d47cfa0fe50e5de185078
8 N942e6b30924a46fb9917a708dea671fb
9 N94319182e0b34935a40dc34895f31307
10 N9e8f40a0b9f340be955db523696c1954
11 Nb39eda50f1454584be74ff11d996a893
12 Ncc2c5b4d7d0c47d583b41d82e1590d6d
13 Nd78fd31f63e54e66a427b36e728caf98
14 Nf2ea5d4affd24895ac9fac4153a8bda4
15 Nf8a7869116704733b38adf85e00459f0
16 Nfa1fb446b79a41ac8e927e13db40e05d
17 anzsrc-for:11
18 anzsrc-for:1103
19 schema:author Nf4b3c9f40680431ab02dee2cf810771c
20 schema:citation sg:pub.10.1007/bf03256922
21 sg:pub.10.1111/j.1572-0241.2003.07486.x
22 sg:pub.10.1111/j.1572-0241.2005.41583.x
23 sg:pub.10.2165/11594330-000000000-00000
24 https://app.dimensions.ai/details/publication/pub.1082321843
25 https://doi.org/10.1002/hep.20251
26 https://doi.org/10.1002/hep.20466
27 https://doi.org/10.1002/hep.21178
28 https://doi.org/10.1002/hep.23276
29 https://doi.org/10.1016/j.ejphar.2015.02.009
30 https://doi.org/10.1016/j.jdiacomp.2012.11.005
31 https://doi.org/10.1016/j.pharmthera.2013.04.003
32 https://doi.org/10.1016/s0002-9343(03)00449-2
33 https://doi.org/10.1016/s0016-5085(98)70599-2
34 https://doi.org/10.1016/s1542-3565(04)00440-9
35 https://doi.org/10.1053/jhep.2003.50193
36 https://doi.org/10.1056/nejmoa060326
37 https://doi.org/10.1056/nejmoa0907929
38 https://doi.org/10.1100/2012/496453
39 https://doi.org/10.1111/j.1464-5491.2009.02666.x
40 https://doi.org/10.1136/bmj.39335.541782.ad
41 https://doi.org/10.1210/jc.2004-1024
42 https://doi.org/10.2337/diabetes.50.8.1844
43 https://doi.org/10.5754/hge11263
44 schema:datePublished 2016-04
45 schema:datePublishedReg 2016-04-01
46 schema:description BACKGROUND: We previously reported that incretin-based drugs, such as dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 (GLP-1) analogs, improved glycemic control and liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients with type 2 diabetes mellitus (T2DM). However, the effect on alanine aminotransferase (ALT) normalization was still limited. AIMS: The aim of this study is to elucidate the effectiveness of sodium-glucose co-transporter 2 (SGLT-2) inhibitors as second-line treatments for NAFLD patients with T2DM who do not respond to incretin-based therapy. METHODS: We retrospectively enrolled 130 consecutive Japanese NAFLD patients with T2DM who were treated with GLP-1 analogs or DPP-4 inhibitors. Among them, 70 patients (53.8 %) had normal ALT levels. Of the remaining 60 patients (46.2 %) who did not have normal ALT levels, 24 (40.0 %) were enrolled in our study and were administered SGLT-2 inhibitors in addition to GLP-1 analogs or DPP-4 inhibitors. We compared changes in laboratory data including ALT levels and body weight at the end of the follow-up. RESULTS: Thirteen patients were administered a combination of SGLT-2 inhibitors with DPP-4 inhibitors, and the remaining 11 patients were administered a combination of SGLT-2 inhibitors with GLP-1 analogs. The median dosing period was 320 days. At the end of the follow-up, body weight (from 84.8 to 81.7 kg, p < 0.01) and glycosylated hemoglobin levels (from 8.4 to 7.6 %, p < 0.01) decreased significantly. Serum ALT levels also decreased significantly (from 62 to 38 IU/L, p < 0.01) with an improvement in the FIB-4 index (from 1.75 to 1.39, p = 0.04). Finally, 14 patients (58.3 %) achieved normalization of serum ALT levels. CONCLUSIONS: Administration of SGLT-2 inhibitors led to not only good glycemic control, but also to a reduction in body weight, normalization of ALT levels, and a reduction in the FIB-4 index even in patients who did not respond to incretin-based therapy.
47 schema:genre research_article
48 schema:inLanguage en
49 schema:isAccessibleForFree false
50 schema:isPartOf N22471a0cb643489db537a0431acd97e6
51 N7f5d73b452d74e22a9345598b98a1460
52 sg:journal.1100199
53 schema:name Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors
54 schema:pagination 313-319
55 schema:productId N020920f5189a4aa8a4934259408f7932
56 N104ea4a60ebc4bfe837d24241851361a
57 N21a7c7e9a00f4221aa6234e994a3869e
58 N755712ca685a41aeab4c7d26a7f1bc4e
59 Ned0fbb56b9d145979cdae0bd46093297
60 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049428929
61 https://doi.org/10.1007/s40261-016-0383-1
62 schema:sdDatePublished 2019-04-11T02:11
63 schema:sdLicense https://scigraph.springernature.com/explorer/license/
64 schema:sdPublisher N513196ee9229409b8df3e9abaca44e78
65 schema:url http://link.springer.com/10.1007%2Fs40261-016-0383-1
66 sgo:license sg:explorer/license/
67 sgo:sdDataset articles
68 rdf:type schema:ScholarlyArticle
69 N020920f5189a4aa8a4934259408f7932 schema:name dimensions_id
70 schema:value pub.1049428929
71 rdf:type schema:PropertyValue
72 N0c7806a5a2c444c5b0868b808155d469 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Sodium-Glucose Transporter 2
74 rdf:type schema:DefinedTerm
75 N104ea4a60ebc4bfe837d24241851361a schema:name doi
76 schema:value 10.1007/s40261-016-0383-1
77 rdf:type schema:PropertyValue
78 N169f5a2bf9544b3f881622a4e805cec9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Non-alcoholic Fatty Liver Disease
80 rdf:type schema:DefinedTerm
81 N21a7c7e9a00f4221aa6234e994a3869e schema:name pubmed_id
82 schema:value 26914659
83 rdf:type schema:PropertyValue
84 N22471a0cb643489db537a0431acd97e6 schema:issueNumber 4
85 rdf:type schema:PublicationIssue
86 N29df11f42e4147e38d7c6f35b862b2e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Female
88 rdf:type schema:DefinedTerm
89 N2ad04e64553b4c178a92f3ac01ff869f rdf:first sg:person.01141347054.93
90 rdf:rest rdf:nil
91 N2df7bae69f5644338428fb078f46718d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Diabetes Mellitus, Type 2
93 rdf:type schema:DefinedTerm
94 N3ce57277b51d453f8dfdf154e250161e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Middle Aged
96 rdf:type schema:DefinedTerm
97 N475a3997182b4b55b406e3736237bc79 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Retrospective Studies
99 rdf:type schema:DefinedTerm
100 N4d42e17b779d47cfa0fe50e5de185078 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Incretins
102 rdf:type schema:DefinedTerm
103 N513196ee9229409b8df3e9abaca44e78 schema:name Springer Nature - SN SciGraph project
104 rdf:type schema:Organization
105 N5390122a83cb466db64f5fdfe2f36d09 rdf:first sg:person.01072014047.79
106 rdf:rest N2ad04e64553b4c178a92f3ac01ff869f
107 N755712ca685a41aeab4c7d26a7f1bc4e schema:name readcube_id
108 schema:value eb77f3ca414118c950dc9cabe52ba8dbbda22e7c63581dda65800f371e66f67d
109 rdf:type schema:PropertyValue
110 N7f5d73b452d74e22a9345598b98a1460 schema:volumeNumber 36
111 rdf:type schema:PublicationVolume
112 N942e6b30924a46fb9917a708dea671fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Weight Loss
114 rdf:type schema:DefinedTerm
115 N94319182e0b34935a40dc34895f31307 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Alanine Transaminase
117 rdf:type schema:DefinedTerm
118 N9e8f40a0b9f340be955db523696c1954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Liver Cirrhosis
120 rdf:type schema:DefinedTerm
121 Nb39eda50f1454584be74ff11d996a893 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Dipeptidyl-Peptidase IV Inhibitors
123 rdf:type schema:DefinedTerm
124 Nc331a5cf123b419b99ca901518213c67 rdf:first sg:person.0741074707.87
125 rdf:rest N5390122a83cb466db64f5fdfe2f36d09
126 Ncc2c5b4d7d0c47d583b41d82e1590d6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Thiophenes
128 rdf:type schema:DefinedTerm
129 Nd78fd31f63e54e66a427b36e728caf98 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Glucagon-Like Peptide 1
131 rdf:type schema:DefinedTerm
132 Ned0fbb56b9d145979cdae0bd46093297 schema:name nlm_unique_id
133 schema:value 9504817
134 rdf:type schema:PropertyValue
135 Nf2ea5d4affd24895ac9fac4153a8bda4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Glucosides
137 rdf:type schema:DefinedTerm
138 Nf4b3c9f40680431ab02dee2cf810771c rdf:first sg:person.0735132461.52
139 rdf:rest Nc331a5cf123b419b99ca901518213c67
140 Nf8a7869116704733b38adf85e00459f0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Male
142 rdf:type schema:DefinedTerm
143 Nfa1fb446b79a41ac8e927e13db40e05d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Humans
145 rdf:type schema:DefinedTerm
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
150 schema:name Clinical Sciences
151 rdf:type schema:DefinedTerm
152 sg:journal.1100199 schema:issn 1173-2563
153 1179-1918
154 schema:name Clinical Drug Investigation
155 rdf:type schema:Periodical
156 sg:person.01072014047.79 schema:affiliation https://www.grid.ac/institutes/grid.415980.1
157 schema:familyName Toda
158 schema:givenName Nobuo
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01072014047.79
160 rdf:type schema:Person
161 sg:person.01141347054.93 schema:affiliation https://www.grid.ac/institutes/grid.415980.1
162 schema:familyName Tagawa
163 schema:givenName Kazumi
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141347054.93
165 rdf:type schema:Person
166 sg:person.0735132461.52 schema:affiliation https://www.grid.ac/institutes/grid.415980.1
167 schema:familyName Ohki
168 schema:givenName Takamasa
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735132461.52
170 rdf:type schema:Person
171 sg:person.0741074707.87 schema:affiliation https://www.grid.ac/institutes/grid.415980.1
172 schema:familyName Isogawa
173 schema:givenName Akihiro
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0741074707.87
175 rdf:type schema:Person
176 sg:pub.10.1007/bf03256922 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041484140
177 https://doi.org/10.1007/bf03256922
178 rdf:type schema:CreativeWork
179 sg:pub.10.1111/j.1572-0241.2003.07486.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049967292
180 https://doi.org/10.1111/j.1572-0241.2003.07486.x
181 rdf:type schema:CreativeWork
182 sg:pub.10.1111/j.1572-0241.2005.41583.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1049736431
183 https://doi.org/10.1111/j.1572-0241.2005.41583.x
184 rdf:type schema:CreativeWork
185 sg:pub.10.2165/11594330-000000000-00000 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069132279
186 https://doi.org/10.2165/11594330-000000000-00000
187 rdf:type schema:CreativeWork
188 https://app.dimensions.ai/details/publication/pub.1082321843 schema:CreativeWork
189 https://doi.org/10.1002/hep.20251 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029810647
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1002/hep.20466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051636461
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1002/hep.21178 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029848202
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1002/hep.23276 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033130882
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/j.ejphar.2015.02.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034689807
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1016/j.jdiacomp.2012.11.005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025708927
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1016/j.pharmthera.2013.04.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016012961
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/s0002-9343(03)00449-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041511618
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/s0016-5085(98)70599-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012749798
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/s1542-3565(04)00440-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023338845
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1053/jhep.2003.50193 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027809788
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1056/nejmoa060326 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029539751
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1056/nejmoa0907929 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029275010
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1100/2012/496453 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048327929
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1111/j.1464-5491.2009.02666.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1022072850
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1136/bmj.39335.541782.ad schema:sameAs https://app.dimensions.ai/details/publication/pub.1008007813
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1210/jc.2004-1024 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022700049
222 rdf:type schema:CreativeWork
223 https://doi.org/10.2337/diabetes.50.8.1844 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003096800
224 rdf:type schema:CreativeWork
225 https://doi.org/10.5754/hge11263 schema:sameAs https://app.dimensions.ai/details/publication/pub.1073100437
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.415980.1 schema:alternateName Mitsui Memorial Hospital
228 schema:name Department of Diabetes and Metabolism, Mitsui Memorial Hospital, Tokyo, Japan
229 Department of Gastroenterology, Mitsui Memorial Hospital, 1 Kandaizumicho, Chiyoda-ku, 101-8643, Tokyo, Japan
230 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...